Hualong He
Sichuan University(CN)State Key Laboratory of Biotherapy
Publications by Year
Research Areas
Epigenetics and DNA Methylation, Cancer-related gene regulation, Ubiquitin and proteasome pathways, Histone Deacetylase Inhibitors Research, Protein Degradation and Inhibitors
Most-Cited Works
- → Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2(2021)115 cited
- → Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis(2018)43 cited
- → Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer(2021)22 cited
- → Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors(2020)16 cited
- → Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity(2019)9 cited
- → Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer(2023)8 cited
- → Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis(2023)8 cited
- → Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer(2022)6 cited
- → Discovery of a Potent FLT3 Inhibitor (E)-4-(3-(3-Fluoro-4-(morpholinomethyl)styryl)-1H-indazol-6-yl)pyridin-2-amine for the Treatment of Acute Myeloid Leukemia with Multiple FLT3 Mutations(2025)3 cited
- → A Facile Total Synthesis of Kilogram-Scale Production of SKLB1039: A Novel andSelective Hexahydroisoquinolin-Containing EZH2 Inhibitor(2022)